Concerns have been raised by senior doctors surrounding the misuse of weight-loss pens in the UK, with some patients ...

It’s unclear what impact a change in presidential administration will have on the proposal to widen access for those with obesity.

The success of GLP-1R-targeting drugs highlights their viability as a treatment approach. Currently, there are four ...

Eli Lilly and Company chief corporate brand officer Lina Polimeni described the new format as a “big evolution” in the ...

Erste Group downgraded Eli Lilly (LLY) to Hold from Buy.Don't Miss our Black Friday Offers:Unlock your investing potential with TipRanks ...

Mounjaro is a treatment for Type 2 diabetes that activates GIP and GLP-1 pathways to help regulate blood sugar. It’s part of ...

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Mohit ...

Pharmaceutical stocks make great additions to any portfolio in any market environment. A good one promises steady revenue ...

Shares of Amgen (NASDAQ: AMGN) recently ticked lower despite a very positive-sounding press release regarding its weight ...

Ministers target obesity, mental health and skills gap in sweeping reforms to tackle economic inactivity and unemployment ...

More than seven million additional Americans could get coverage for popular drugs such as Zepbound and Wegovy under the ...